Aman Chauhan
Director of the Neuroendocrine Tumor Program at Sylvester Cancer Center in Miami, involved in translational and clinical research on molecular profiling and novel therapies for high-grade neuroendocrine cancers.
Top 3 podcasts with Aman Chauhan
Ranked by the Snipd community
Dec 22, 2025 • 35min
Hybrid Neuroendocrine Cancers: Pathology, Grade Transformation, and Emerging Therapies
Renuka Iyer, a neuroendocrine tumor expert and Chief of GI Oncology at Roswell Park, discusses the importance of expert pathology reviews and accurate NET classification. Shagufta Shaheen, a GI medical oncologist at Stanford, highlights the management of mixed neuroendocrine neoplasms and therapy-driven dedifferentiation. Aman Chauhan, Director of the Neuroendocrine Tumor Program in Miami, shares insights on novel therapies, including DLL3-targeted strategies and CAR-T early trials, revealing exciting advances in the treatment landscape.
Sep 4, 2025 • 1h 7min
Recap of 9/3/25 Livestream Q&A with Dr. Aman Chauhan!
Dr. Aman Chauhan, a leading medical oncologist at Sylvester Comprehensive Cancer Center, shares valuable insights on neuroendocrine tumors. He discusses recent advancements in diagnosis and treatment, emphasizing the importance of tailored medical advice for individual cases. Dr. Chauhan delves into the risks associated with skull metastases and the implications of different treatment options like alpha versus beta PRRT. He highlights the role of somatostatin analogues and telemedicine in improving patient care, making complex topics accessible and engaging.
May 27, 2025 • 38min
Promising Advances in NEC Research and Treatment
Dr. Renuka Iyer, a GI and neuroendocrine oncologist, and Dr. Aman Chauhan, a leader in neuroendocrine tumor research, share insights on groundbreaking advancements in neuroendocrine carcinoma treatments. They delve into the biological distinctions between pulmonary and extrapulmonary types and discuss innovative therapies like DLL3 targeting and oncolytic virus studies. The importance of clinical trials and tumor profiling is emphasized, highlighting their critical role in improving patient outcomes and presenting new therapeutic options for challenging cases.
